Navigation Links
IRIDEX Announces Second Quarter 2009 Conference Call and Release Date
Date:8/6/2009

MOUNTAIN VIEW, Calif., Aug. 6 /PRNewswire-FirstCall/ -- IRIDEX Corporation (NASDAQ: IRIX) today announced that it will release its second quarter 2009 financial results after the market closes on Thursday, August 13, 2009. In conjunction with the release, the Company will host a conference call with the investment community at 5:00 p.m. Eastern Time on Thursday, August 13, 2009 to discuss the results of the quarter and other business developments.

Interested parties may access the live conference call via telephone by dialing (877) 941-0843 U.S. or (480) 629-9643 (International) and quoting Conference ID 4133387, or by visiting the Company's website at www.iridex.com. A telephone replay will be available beginning on Thursday, August 13, 2009 through Thursday, August 20, 2009 by dialing (800) 406-7325 (US) or (303) 590-3030 (International) and entering Access Code 4133387.

About IRIDEX

IRIDEX Corporation is a leading worldwide provider of therapeutic based laser systems, consumable laser probes and delivery devices to treat eye diseases in ophthalmology and skin disorders in the aesthetics market. IRIDEX products are sold in the United States through a direct sales force and internationally through a combination of a direct sales force and a network of approximately 100 independent distributors into 107 countries. For further information, visit the Company's website at www.iridex.com.


'/>"/>
SOURCE IRIDEX Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related medicine news :

1. IRIDEX Reports First Quarter 2009 Financial Results
2. IRIDEX Announces First Quarter 2009 Conference Call and Release Date
3. IRIDEX Announces Shipment of New IQ 577(TM) Laser Systems
4. IRIDEX Reports Fourth Quarter and Full Year 2008 Financial Results
5. IRIDEX Announces Fourth Quarter and Full Year 2008 Conference Call and Release Date
6. IRIDEX Reports Third Quarter 2008 Financial Results
7. IRIDEX Announces Third Quarter 2008 Conference Call and Release Date
8. IRIDEX Reports First Quarter 2008 Financial Results
9. IRIDEX Announces First Quarter 2008 Conference Call and Release Date
10. IRIDEX Reports Fourth Quarter and Full Year 2007 Financial Results
11. IRIDEX Announces Fourth Quarter and Full Year 2007 Conference Call and Release Date
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/2/2014)... have pinpointed a molecule that may trigger potentially life-threatening ... say this finding could offer a target for new ... Most asthma attacks (80 percent to 90 percent) are ... the British researchers. Most of these are rhinoviruses, which ... The researchers found that a specific molecule called IL-25 ...
(Date:10/2/2014)... By Dennis Thompson ... -- A newborn,s risk of developing celiac disease isn,t reduced ... found in wheat called gluten to an infant,s diet help ... a pair of new studies in the Oct. 2 ... put to rest hopes that a child could avoid celiac ...
(Date:10/2/2014)... discovery by scientists at The University of Nottingham could ... of painkiller. , A drug resulting from the research, ... would offer new hope to sufferers of chronic pain ... effective painkillers are currently available. , The work, led ... Life Sciences, in collaboration with David Bates, Professor of ...
(Date:10/1/2014)... today in the Journal of the American Medical ... years with moderate or severe chronic knee pain, acupuncture ... University of Melbourne randomly assigned 282 patients (50 years ... or sham or pretend laser treatment. , Treatments ... blinded to laser and sham (inactive) laser acupuncture. , ...
(Date:10/1/2014)... 1, 2014) Despite a policy focus on ... disabilities, this vulnerable population continues to have significant ... The Journal of the American Dental Association , ... Tufts University School of Dental Medicine report on ... at-home oral care provided by caregivers to adults ...
Breaking Medicine News(10 mins):Health News:New Clues to How Colds Can Spur Asthma Attacks 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 2Health News:Infant's Early Diet Doesn't Change Celiac Disease Risk, Study Finds 3Health News:Medical discovery first step on path to new painkillers 2Health News:Study finds acupuncture does not improve chronic knee pain 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 2Health News:To improve oral health of adults with developmental disabilities, support caregivers 3
... America (GSA) the nation,s largest interdisciplinary organization ... Vishwa Deep Dixit, DVM, PhD, of the Pennington Biomedical ... Shock New Investigator Award. The distinguished honor is ... through basic biological research. It was established in 1986 ...
... The immunochemical fecal occult blood test (iFOBT) is ... not in the upper gastrointestinal (GI) tract, confirms a ... Journal ) (pre-embargo link only) http://www.cmaj.ca/site/embargo/cmaj101248.pdf . ... noninvasive tool to screen for bleeding without symptoms in ...
... Hydrogen sulfide is a foul-smelling gas with an odor resembling ... substance is generally associated with decaying vegetation, sewers and noxious ... it also plays a critical role in protecting blood ... study from the University of Texas Medical Branch at Galveston. ...
... By Denise Mann HealthDay Reporter , TUESDAY, Aug. ... and replace damaged discs -- at least in rats, a ... implants like these, made of cells and collagen, may one day ... They might also last longer than the more artificial replacement ...
... of Nottingham scientist who uses fruit flies to study the ... Research UK. Dr Marios Georgiou, lecturer in cell biology ... a five year Career Establishment Award of 600,000. The award ... to become the eminent cancer scientists of the future. ...
... By Amanda Gardner HealthDay Reporter , MONDAY, ... leading pulmonary associations have issued new guidelines for the ... of the world,s leading killers. While the recommendations ... they differ little from previous guidelines and are meant ...
Cached Medicine News:Health News:Dixit to receive GSA's 2011 Nathan Shock New Investigator Award 2Health News:Noninvasive fecal occult blood test effective screen for lower GI tract lesions 2Health News:Scientists show 'swamp gas' protects blood vessels from complications of diabetes 2Health News:Bio-Engineered Spinal Discs Appear Successful in Rats 2Health News:Bio-Engineered Spinal Discs Appear Successful in Rats 3Health News:Nottingham scientist wins major cancer research award 2Health News:Nottingham scientist wins major cancer research award 3Health News:New Guidelines for Spotting, Treating COPD Released 2
(Date:10/2/2014)... , Oct. 2, 2014  Isis Pharmaceuticals, Inc. ... webcast:What: , Webcast and conference call to provide ... clinical studies of ISIS-SMN Rx in infants ... will be presented on the morning (CEST) of ... Muscle Society in Berlin, GermanyWhen:Friday, October 10 at ...
(Date:10/2/2014)... Ireland , Oct. 2, 2014   West ... a global leader in innovative solutions for injectable drug ... manufacturing operations to include a new site in ... produce packaging components for insulin injector cartridges and other ... from pharmaceutical and biotech customers. Once operational, this new ...
(Date:10/2/2014)... 2014   Intarcia Therapeutics, Inc. today announced ... 3 clinical trials for ITCA 650 (exenatide, delivered continuously ... mini-pump). The first trial, FREEDOM-1, was a placebo-controlled, double-blind ... safety of ITCA 650 in patients with type 2 ... be significantly superior to placebo for both 40 mcg ...
Breaking Medicine Technology:Isis Pharmaceuticals to Host Webcast to Discuss ISIS-SMN Rx Results Presented at the World Muscle Society Congress 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 2West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 3West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 4West Announces Plans for a New Pharmaceutical Component Manufacturing Plant in Ireland 5Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 2Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 3Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 4Intarcia Announces Two Positive Phase 3 Trials for ITCA 650 in Type 2 Diabetes: FREEDOM-1 and FREEDOM-1 High Baseline (HBL) Study Results 5
... , BOSTON, Nov. 17 ... and information management solutions, today announced that it will showcase ... (IDNs) at the 2009 Radiological Society of North America (RSNA) ... IL. AMICAS will be in the North Hall in booth ...
... HistoRx today announced that the Company,s proprietary AQUA technology, ... was noted in a recent National Comprehensive Cancer ... testing in breast cancer as one of the "... promising ... PgR in breast cancer tissue." Experts from the country,s ...
Cached Medicine Technology:AMICAS' Enterprise Image Management Solutions To Be Showcased at RSNA 2009 2AMICAS' Enterprise Image Management Solutions To Be Showcased at RSNA 2009 3AQUA(R) Technology Recognized as 'Promising New Strategy' for Hormone Receptor Testing in Breast Cancer by NCCN Task Force 2
Tying forceps with 6.5 mm tying platform. Round handle with flats provide flexibility of round handle with the stability of a flat handle. Straight shafts. Overall length 3.9 inches....
Curved shafts with 4 mm tying platform. Serrated handle with dull finish. Manufactured in titanium. Overall length 3.3 inches....
Straight 6 mm platform. McPherson handle. Manufactured in titanium. Overall length 3.3 inches....
Curved shafts and tips with 6.5 mm tying platform. Flat serrated handle with dull finish. Overall length 3.9 inches. Overall length 3.9 inches....
Medicine Products: